Sugi Predict

Sugi Predict / Compounds / SCHEMBL90412

SCHEMBL90412

SCHEMBL90412

COC(=O)c1cc(O)cc(OCc2ccccc2)c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.69
▸ HPGD P15428 1/20 0.69
▸ MEN1 O00255 3/20 0.60
▸ KMT2A Q03164 3/20 0.60
▸ MAOB P27338 3/20 0.55
▸ CA12 O43570 1/20 0.54
▸ CA1 P00915 1/20 0.54
▸ CA2 P00918 1/20 0.54
▸ CA7 P43166 1/20 0.54
▸ CA9 Q16790 1/20 0.54
▸ CA14 Q9ULX7 1/20 0.54
▸ NR4A2 P43354 2/20 0.54
▸ SMN1; SMN2 Q16637 4/20 0.53
▸ SMPD1 P17405 1/20 0.52
▸ MRGPRX4 Q96LA9 2/20 0.51
▸ NPC1 O15118 3/20 0.50
▸ RAB9A P51151 3/20 0.50
▸ PTPN1 P18031 1/20 0.50
▸ CYP1A1 P04798 1/20 0.50
▸ CYP1A2 P05177 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29475634 1.00 LMNA (0.69) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL391547 0.92 MEN1 (0.71) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL183994 0.92 LMNA (0.70) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL9324726 0.92 LMNA (0.60) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL8663810 0.92 LMNA (0.59) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL29788280 0.88 LMNA (0.65) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL3129603 0.88 MEN1 (0.74) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL340311 0.88 LMNA (0.65) LMNAHPGDMEN1KMT2AMAOB
SCHEMBL1107602 0.87 SMPD1 (0.56) LMNAHPGDMEN1KMT2ACA12
SCHEMBL3604210 0.87 MAOB (0.55) LMNAHPGDMEN1KMT2AMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 299 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119233964-A Single component delivery system for nucleic acids 宾夕法尼亚大学理事会 2024-12-31 — — CN disclosed
CN-118930421-A Deuterated or fluoroindenone TNF-alpha inhibitor and preparation method and application thereof 江苏安杰泰生物科技有限公司 2024-11-12 — — CN disclosed
CN-118852134-A 3-Phenyl-4-formate substituted benzofuran derivatives, preparation method, pharmaceutical composition and application thereof 中国医学科学院药物研究所 2024-10-29 — — CN disclosed
US-20240252677-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 2024-08-01 — — US disclosed
EP-4347550-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS The Trustees of the University of Pennsylvania (US) 2024-04-10 — — EP disclosed
US-11634375-B2 Prenylated hydroxystilbenes Kynan Duke IP, LLC (US) 2023-04-25 — — US disclosed
US-11583507-B2 Direct AMPK activator compounds SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-02-21 — — US disclosed
US-11583507-B2 Direct AMPK activator compounds SOCIETE DES PRODUITS NESTLE S.A. (CH) 2023-02-21 — — US disclosed
WO-2022251191-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-12-01 — — WO disclosed
WO-2022251191-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2022-12-01 — — WO disclosed
WO-2006040528-A1 PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2006040528-A1 PHENOXY BENZAMIDE COMPOUNDS WITH UTILITY IN THE TREATMENT OF TYPE 2 DIABETES AND OBESITY ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2006040529-A1 BENZAMIDE DERIVATIVES THAT ACT UPON THE GLUCOKINASE ENZYME ASTRAZENECA AB (SE) 2006-04-20 — — WO disclosed
WO-2005121110-A1 HETROARYL BENZAMIDE DERIVATIVES FOR USE AS GLK ACTIVATORS IN THE TREATMENT OF DIABETES ASTRAZENECA AB (SE) 2005-12-22 — — WO disclosed
WO-2005080359-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS ASTRAZENECA AB (SE) 2005-09-01 — — WO disclosed
WO-2005080359-A1 BENZAMIDE DERIVATIVES AND THEIR USE AS GLUCOKINAE ACTIVATING AGENTS ASTRAZENECA AB (SE) 2005-09-01 — — WO disclosed
WO-2005056530-A1 BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS ASTRAZENECA AB (SE) 2005-06-23 — — WO disclosed
WO-2005054200-A1 BENZOYL AMINO PYRIDYL CARBOXYLIC ACID DERIVATIVES USEFUL AS GLUCOKINASE (GLK) ACTIVATORS ASTRAZENECA AB (SE) 2005-06-16 — — WO disclosed
WO-2005054233-A1 BENZOYL AMINO PYRIDIL CARBOXYLIC ACID DERIVATIVES AS GLUOKINASE ACTIVATORS ASTRAZENECA AB (SE) 2005-06-16 — — WO disclosed
WO-2005044801-A1 PYRIDINE CARBOXYLIC ACID DERIVATIVES AS GLUCOKINASE MODULATORS ASTRAZENECA AB (SE) 2005-05-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240252677-A1 ONE-COMPONENT DELIVERY SYSTEM FOR NUCLEIC ACIDS TLR3, TLR9, ADAR LMNA 2652/4885HPGD 4615/4885MEN1 1712/4885
US-11583507-B2 Direct AMPK activator compounds PRKAG2, AK2, PRKAG3 LMNA 2183/4885HPGD 2285/4885MEN1 2096/4885
US-11634375-B2 Prenylated hydroxystilbenes HCLS1, IWS1, UTS2R LMNA 594/4885HPGD 440/4885MEN1 1465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.